AbbVie completes $10.9 billion acquisition of Apogee Therapeutics as UK launches drug pricing pilot
AbbVie, the Chicago-based pharmaceutical company, finalized its purchase of Apogee Therapeutics for $10.9 billion last month, ending a multi-year negotiation process.
The transaction brings Apogee’s drug development programs under AbbVie’s portfolio, broadening the larger firm’s pipeline and research capabilities.
At the same time, the United Kingdom has begun a pilot program aimed at testing new drug pricing mechanisms, signaling potential shifts in market reimbursement models.
The briefing also noted other industry updates, including news related to Brii Biosciences, though details were not provided.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that